It improves insulin sensitivity and reduces risk of gestational diabetes, lowers blood pressure and reduces preeclampsia risk, improves lipid profiles, reduces inflammation, enhances cardiovascular health, and decreases risks of pregnancy complications
On July 18, 2025, FDA followed through by issuing Genentech a complete response letter for glofitamab (Columvi) plus chemotherapy in diffuse large B-cell lymphoma, directly citing the Starglo population-representativeness concerns raised by the advisory committee ( [110] )
They found "no studies that administered BPC-157 to humans via the proposed oral, SC, nasal, or transdermal ROA" [12]
Part 2 of the ESSENCE trial will continue with expected readout in 2029
This was done with brain images for both the control (saline) group and treated (BPC 157) group of rats at same intervals after the application and at the time of sacrifice